Potential Danger of an almost 4000% IgG4 rise in COVID-19 vaccination
What is IgG4 antibody and why would it rise almost 4000% after covid vaccination?
Vejon COVID-19 Review is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
The extraordinary rise in IgG4 is one important mechanism of post vaccination immunosuppressive findings
Yes - as you point out, it can dampen the hyperinflammation found in the second, severe hypersensitivity stage of Covid19 characterised by ‘cytokine storm’
But the long term danger especially from repeated dosing ( ‘boosting’) is persistent immunosuppressant effects, not a desirable status - and we could probably be seeing the aftermath
There are reports of strange cancers, rapid advances of extant malignancies, unusual infections etc that are probably adding to, if not the primary cause ( along with blood clotting issues, cardiac and other organ toxicities, neurological and psychiatric abnormalities, fertility and miscarriages etc ) the general finding of markedly raised excess mortality figures - not ascribable to Covid19 itself - after the vaccines were introduced
Several analyses describe the LNP/mRNA vaccines as the likely culprits and we must await full access to government statistics to be certain of causality
But it doesn’t look good to me
"Serum IgG4 level predicts COVID-19 related mortality. (A) Serum IgG4 concentration, but not IgG1, IgG2, and IgG3, is significantly higher in COVID-19 non-survivors compared to survivors (p value < 0.05). (B) Increased serum IgG4 level (> 700 mg/L) and IgG4/IgG1 ratio (> 0.05) are associated with increased mortality in COVID-19 patients (p value < 0.05 for both survival analyses). (C) Serum IgG4 concentration positively correlates with serum IL-6 levels (p value < 0.05)."
https://www.ejinme.com/cms/attachment/57fc4019-3fe0-4857-b413-6550361288cf/gr1.jpg
"Despite intrinsic limitations mainly related to the limited number of patients enrolled, our study identifies IgG4 antibodies as a possible additional overlooked variable of the humoral immune response against SARS-CoV-2 associated with COVID-19 progression."
https://www.ejinme.com/article/S0953-6205(21)00312-5/fulltext